Key Takeaways
- • McGill University's D2R (DNA to RNA) initiative hosts a November 28, 2025 hybrid seminar on venture capital investing in early-stage life science, featuring Inès Holzbaur, Founder and Managing Partner of AmorChem, as the keynote speaker.
- • Holzbaur will address the critical gap between academic discovery and private investment, focusing on how venture capitalists evaluate translational research value and identify investment-ready opportunities from laboratory discoveries.
- • The seminar targets researchers and academics seeking to understand investor frameworks, deal structuring, and the criteria that distinguish fundable life science concepts from those unable to attract venture capital.
- • Holzbaur brings institutional credibility through her founding role at AmorChem, board leadership at NuChem Sciences (2011–2019), and transaction experience with major pharmaceutical acquirers including Hoffman LaRoche and Vertex Pharmaceuticals.
- • The event offers dual attendance options—in-person at D2R Offices (1010 Sherbrooke St. West, Suite 1800) or virtual via Zoom—accommodating both local and remote participants from the academic and investment communities.
Summary
McGill University's D2R Investor Series is hosting a hybrid educational seminar on November 28, 2025, designed to demystify venture capital investment processes for researchers and academics exploring commercialization pathways. The seminar, titled "Venture Capital Demystified: Investment Insights with Inès Holzbaur," addresses a structural challenge in the research-to-market pipeline: the gap between billions of dollars invested annually by funding agencies in basic and translational research and the limited clarity surrounding how investors evaluate early-stage scientific discoveries for private capital deployment.
Inès Holzbaur, the featured speaker, brings substantial experience in early-stage life science venture investing and pharmaceutical transactions. As Founder and Managing Partner of AmorChem, she designed the fund's investment model, operational framework, and deal evaluation processes. She previously served as Chair of NuChem Sciences from 2011 to 2019 and has been instrumental in major transactions with pharmaceutical leaders Hoffman LaRoche and Vertex Pharmaceuticals. Her background positions her to provide credible insight into how investment decisions are made at the intersection of academic research and commercial viability.
The seminar curriculum is structured around three core learning objectives: understanding how venture capital investors operate, identifying the characteristics of research ideas that attract venture capital attention, and evaluating the translational and commercial value of scientific opportunities. Participants will gain practical frameworks for moving laboratory discoveries toward investment readiness, addressing a common knowledge gap among academic researchers unfamiliar with investor expectations, deal structures, and commercialization timelines.
The event is accessible both in-person at D2R Offices (1010 Sherbrooke St. West, Suite 1800, 18th floor) and remotely via Zoom, running from 11:00 to 13:00 EST. This dual-format approach facilitates participation from geographically dispersed academic and investor audiences. The initiative reflects McGill's broader commitment to bridging the academic-investment divide through structured educational programming and networking opportunities for early-stage researchers seeking to navigate venture financing.
Inès Holzbaur, the featured speaker, brings substantial experience in early-stage life science venture investing and pharmaceutical transactions. As Founder and Managing Partner of AmorChem, she designed the fund's investment model, operational framework, and deal evaluation processes. She previously served as Chair of NuChem Sciences from 2011 to 2019 and has been instrumental in major transactions with pharmaceutical leaders Hoffman LaRoche and Vertex Pharmaceuticals. Her background positions her to provide credible insight into how investment decisions are made at the intersection of academic research and commercial viability.
The seminar curriculum is structured around three core learning objectives: understanding how venture capital investors operate, identifying the characteristics of research ideas that attract venture capital attention, and evaluating the translational and commercial value of scientific opportunities. Participants will gain practical frameworks for moving laboratory discoveries toward investment readiness, addressing a common knowledge gap among academic researchers unfamiliar with investor expectations, deal structures, and commercialization timelines.
The event is accessible both in-person at D2R Offices (1010 Sherbrooke St. West, Suite 1800, 18th floor) and remotely via Zoom, running from 11:00 to 13:00 EST. This dual-format approach facilitates participation from geographically dispersed academic and investor audiences. The initiative reflects McGill's broader commitment to bridging the academic-investment divide through structured educational programming and networking opportunities for early-stage researchers seeking to navigate venture financing.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.